

February 19, 2026

Analyst Meet Update

■ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	ACCUMULATE		ACCUMULATE	
Target Price	7,038		7,038	
Sales (Rs. m)	38,719	44,681	38,719	44,681
% Chng.	-	-	-	-
EBITDA (Rs. m)	11,953	14,153	11,953	14,153
% Chng.	-	-	-	-
EPS (Rs.)	148.1	179.3	148.1	179.3
% Chng.	-	-	-	-

Key Financials - Consolidated

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	23,494	32,130	38,719	44,681
EBITDA (Rs. m)	5,337	10,372	11,953	14,153
Margin (%)	22.7	32.3	30.9	31.7
PAT (Rs. m)	2,886	6,506	7,345	8,893
EPS (Rs.)	58.2	131.2	148.1	179.3
Gr. (%)	32.0	125.4	12.9	21.1
DPS (Rs.)	12.0	27.8	30.5	36.9
Yield (%)	0.2	0.4	0.5	0.6
RoE (%)	11.5	22.5	21.3	21.7
RoCE (%)	10.6	19.6	18.8	20.4
EV/Sales (x)	14.1	10.4	8.6	7.4
EV/EBITDA (x)	62.0	32.3	27.9	23.4
PE (x)	109.8	48.7	43.1	35.6
P/BV (x)	12.1	10.0	8.5	7.1

Key Data

NAFL.BO | NFIL IN

52-W High / Low	Rs.6,965 / Rs.3,566
Sensex / Nifty	83,734 / 25,819
Market Cap	Rs.327bn / \$ 3,609m
Shares Outstanding	51m
3M Avg. Daily Value	Rs.1261.48m

Shareholding Pattern (%)

Promoter's	27.11
Foreign	23.74
Domestic Institution	28.09
Public & Others	21.06
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	3.7	26.7	56.3
Relative	3.5	22.9	41.8

Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

Saurabh Ahire

saurabhahire@plindia.com | 91-22-66322537

Tejas Kadam

tejaskadam@plindia.com | 91-22-66322222

Multiple growth levers in FY27–28

Quick Pointers:

- Chemours Phase 2 capex has the potential to reach ~10x of the current investment of USD14mn
- Fermion's annual run-rate is expected to increase in FY27 from the previously guided number of ~USD40mn

We attended the analyst meet for Navin Fluorine International Ltd (NFIL) and, based on our interaction with the management, the company appears well positioned for a strong multi-year growth trajectory, supported by a robust CDMO pipeline, expansion of key refrigerant gas capacities, and sustained momentum in the agchem segment. The Chemours partnership, with an initial investment of USD14mn, offers significant potential, with Phase 2 capex potentially scaling up to ~10x as demand for liquid cooling fluids gains traction. Additionally, high-grade HF and the upcoming R32-equivalent plant are expected to materially enhance performance from FY28, aided by expanded AHF capacity of ~60,000mtpa, which will support both external sales and value-added downstream integration. Overall, with diversified growth drivers across CDMO, agchem and refrigerants, NFIL is shifting its focus toward short-cycle, high-value products in the coming years. We expect revenue/EBITDA/PAT to clock a CAGR of 18%/17%/15% over FY26–28E and maintain our 'Accumulate' rating on the stock with TP of Rs7,038, valuing it at 41x Dec'27E EPS.

- Limited downside risks to R32 pricing:** The management expects ~15,000mtpa of R32-equivalent capacity to come on stream in Q3FY27, contributing to 4–5 months of revenue in FY27. The management also indicated that R32 prices are not expected to see any major downside even after new capacity additions. Domestic realizations are currently superior to export markets. With the commissioning of 40,000mtpa of new AHF capacity, surplus AHF volumes of 6–8ktpa are expected to be sold externally in FY27. However, the company aims to utilize maximum AHF for value-added downstream products. Additionally, HFO volumes still have headroom for ~20% growth, and the company has no immediate debottlenecking plans. NFIL is focusing on product diversification in collaboration with Honeywell, to reduce dependence on a single HFO molecule.
- Strong CDMO pipeline and growth visibility:** The company has a pipeline of 10–15 molecules, of which 2–3 are likely to enter the final stages of regulatory approval over the next 2–3 years. Fermion's annual run-rate is expected to increase in FY27 from the previously guided number of ~USD40mn.
- Chemours Phase 2 capex can reach ~10x current investment:** The Chemours project (Opteon) is progressing as planned and is expected to be commissioned in Q1FY27, with NFIL's plant becoming the first global capacity for Chemours for this product. The management highlighted that Chemours Phase 2 capex could reach ~10x of the current investment (USD14mn) once demand for the 2-phase immersion fluid picks up. Project Nectar is expected to achieve ~50% utilization in FY26, scale up to ~75% by end-FY27, and reach full utilization by FY28, providing meaningful earnings ramp-up over the medium term.

Financials

Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Net Revenues	23,494	32,130	38,719	44,681
YoY gr. (%)	13.8	36.8	20.5	15.4
Cost of Goods Sold	10,386	13,334	16,262	18,766
Gross Profit	13,108	18,796	22,457	25,915
Margin (%)	55.8	58.5	58.0	58.0
Employee Cost	2,967	3,026	3,147	3,273
Other Expenses	4,804	5,398	7,357	8,489
EBITDA	5,337	10,372	11,953	14,153
YoY gr. (%)	34.0	94.3	15.2	18.4
Margin (%)	22.7	32.3	30.9	31.7
Depreciation and Amortization	1,194	1,329	1,743	1,968
EBIT	4,143	9,043	10,211	12,185
Margin (%)	17.6	28.1	26.4	27.3
Net Interest	779	1,176	1,180	1,121
Other Income	437	643	697	715
Profit Before Tax	3,801	8,510	9,728	11,779
Margin (%)	16.2	26.5	25.1	26.4
Total Tax	915	2,004	2,383	2,886
Effective tax rate (%)	24.1	23.6	24.5	24.5
Profit after tax	2,886	6,506	7,345	8,893
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	2,886	6,506	7,345	8,893
YoY gr. (%)	32.2	125.4	12.9	21.1
Margin (%)	12.3	20.2	19.0	19.9
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	2,886	6,506	7,345	8,893
YoY gr. (%)	32.2	125.4	12.9	21.1
Margin (%)	12.3	20.2	19.0	19.9
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	2,886	6,506	7,345	8,893
Equity Shares O/s (m)	50	50	50	50
EPS (Rs)	58.2	131.2	148.1	179.3

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Non-Current Assets				
Gross Block	30,225	36,225	41,225	46,225
Tangibles	30,225	36,225	41,225	46,225
Intangibles	-	-	-	-
Acc: Dep / Amortization	4,721	6,050	7,792	9,760
Tangibles	4,721	6,050	7,792	9,760
Intangibles	-	-	-	-
Net fixed assets	25,505	30,176	33,433	36,465
Tangibles	25,505	30,176	33,433	36,465
Intangibles	-	-	-	-
Capital Work In Progress	3,498	3,498	3,498	3,498
Goodwill	-	-	-	-
Non-Current Investments	4,799	4,799	4,799	4,799
Net Deferred tax assets	(754)	(754)	(754)	(754)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	3,224	3,864	4,753	5,421
Trade receivables	5,824	8,715	10,502	12,119
Cash & Bank Balance	405	1,951	1,992	3,799
Other Current Assets	5,048	5,048	5,048	5,048
Total Assets	48,304	58,051	64,025	71,150
Equity				
Equity Share Capital	99	99	99	99
Other Equity	26,163	31,493	37,327	44,390
Total Network	26,262	31,592	37,426	44,490
Non-Current Liabilities				
Long Term borrowings	14,407	20,170	19,162	18,204
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	3,270	596	733	836
Other current liabilities	3,611	4,938	5,950	6,867
Total Equity & Liabilities	48,304	58,051	64,025	71,150

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	3,801	8,715	9,728	11,779
Add. Depreciation	1,194	1,329	1,743	1,968
Add. Interest	779	1,176	1,180	1,121
Less Financial Other Income	437	643	697	715
Add. Other	8	-	-	-
Op. profit before WC changes	5,783	11,220	12,650	14,868
Net Changes-WC	933	(4,876)	(1,527)	(1,266)
Direct tax	(780)	(2,004)	(2,383)	(2,886)
Net cash from Op. activities	5,935	4,339	8,740	10,716
Capital expenditures	(5,611)	(6,000)	(5,000)	(5,000)
Interest / Dividend Income	17	-	-	-
Others	484	-	-	-
Net Cash from Invst. activities	(5,111)	(6,000)	(5,000)	(5,000)
Issue of share cap. / premium	-	-	-	-
Debt changes	1,014	5,763	(1,009)	(958)
Dividend paid	(595)	(1,381)	(1,511)	(1,830)
Interest paid	(786)	(1,176)	(1,180)	(1,121)
Others	-	-	-	-
Net cash from Fin. activities	(366)	3,207	(3,699)	(3,909)
Net change in cash	458	1,546	41	1,807
Free Cash Flow	324	(1,661)	3,740	5,716

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Per Share(Rs)				
EPS	58.2	131.2	148.1	179.3
CEPS	82.3	158.0	183.2	219.0
BVPS	529.5	636.9	754.6	897.0
FCF	6.5	(33.5)	75.4	115.2
DPS	12.0	27.8	30.5	36.9
Return Ratio(%)				
RoCE	10.6	19.6	18.8	20.4
ROIC	8.1	15.3	14.8	16.2
RoE	11.5	22.5	21.3	21.7
Balance Sheet				
Net Debt : Equity (x)	0.5	0.6	0.5	0.3
Net Working Capital (Days)	90	136	137	136
Valuation(x)				
PER	109.8	48.7	43.1	35.6
P/B	12.1	10.0	8.5	7.1
P/CEPS	77.6	40.4	34.9	29.2
EV/EBITDA	62.0	32.3	27.9	23.4
EV/Sales	14.1	10.4	8.6	7.4
Dividend Yield (%)	0.2	0.4	0.5	0.6


Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Net Revenue	7,009	7,254	7,584	8,924
YoY gr. (%)	16.4	38.5	46.3	47.2
Raw Material Expenses	3,211	3,077	3,129	3,677
Gross Profit	3,799	4,177	4,455	5,247
Margin (%)	54.2	57.6	58.7	58.8
EBITDA	1,787	2,068	2,462	3,076
YoY gr. (%)	62.4	106.1	129.3	108.8
Margin (%)	25.5	28.5	32.5	34.5
Depreciation / Depletion	353	352	366	362
EBIT	1,435	1,716	2,096	2,714
Margin (%)	20.5	23.6	27.6	30.4
Net Interest	282	304	303	283
Other Income	118	139	182	156
Profit before Tax	1,271	1,551	1,975	2,587
Margin (%)	18.1	21.4	26.0	29.0
Total Tax	320	379	491	529
Effective tax rate (%)	25.2	24.5	24.9	20.4
Profit after Tax	950	1,172	1,484	2,059
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	950	1,172	1,484	2,263
YoY gr. (%)	35.0	128.8	152.2	170.7
Margin (%)	13.6	16.2	19.6	25.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	950	1,172	1,484	2,263
YoY gr. (%)	35.0	128.8	152.2	170.7
Margin (%)	13.6	16.2	19.6	25.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	-	-	-	-
Avg. Shares O/s (m)	50	50	50	50
EPS (Rs)	19.0	23.4	29.7	45.3

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	09-Feb-26	Accumulate	7,038	6,598
2	07-Jan-26	Accumulate	6,722	5,751
3	20-Nov-25	Accumulate	6,441	6,025
4	14-Nov-25	Accumulate	6,441	6,015
5	30-Oct-25	Accumulate	5,601	5,009
6	07-Oct-25	Accumulate	5,196	4,568
7	31-Jul-25	Accumulate	5,559	5,198
8	07-Jul-25	Accumulate	5,161	4,933
9	10-May-25	Accumulate	5,161	4,595
10	08-Apr-25	Accumulate	4,454	3,880

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Accumulate	466	430
2	Bharat Petroleum Corporation	Accumulate	406	373
3	Bharti Airtel	Accumulate	2,313	2,038
4	Clean Science and Technology	Hold	841	861
5	Deepak Nitrite	Hold	1,673	1,634
6	Fine Organic Industries	BUY	5,117	4,423
7	GAIL (India)	BUY	190	160
8	Gujarat Fluorochemicals	Hold	3,434	3,360
9	Gujarat Gas	Accumulate	422	399
10	Gujarat State Petronet	Hold	296	303
11	Hindustan Petroleum Corporation	Accumulate	457	428
12	Indian Oil Corporation	Accumulate	195	176
13	Indraprastha Gas	Accumulate	191	167
14	Jubilant Ingrevia	Hold	657	626
15	Laxmi Organic Industries	Reduce	125	143
16	Mahanagar Gas	Accumulate	1,305	1,181
17	Mangalore Refinery & Petrochemicals	Accumulate	162	151
18	Navin Fluorine International	Accumulate	7,038	6,598
19	NOCIL	Hold	159	153
20	Oil & Natural Gas Corporation	Accumulate	297	267
21	Oil India	Accumulate	527	479
22	Petronet LNG	Hold	288	290
23	Reliance Industries	BUY	1,688	1,423
24	SRF	Hold	2,894	2,883
25	Vinati Organics	Accumulate	1,671	1,496

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II, Mr. Tejas Kadam- BCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II, Mr. Tejas Kadam- BCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com